Reuters logo
2 months ago
BRIEF-Boehringer Ingelheim says Phase III results show clinical equivalence of adalimumab biosimilar candidate to Humira
June 14, 2017 / 1:18 PM / 2 months ago

BRIEF-Boehringer Ingelheim says Phase III results show clinical equivalence of adalimumab biosimilar candidate to Humira

June 14 (Reuters) - Boehringer Ingelheim:

* Study results confirms that its BI 695501 and Humira have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis

* Boehringer Ingelheim presents Phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to Humira

* Boehringer Ingelheim - co-primary endpoints at weeks 12 and 24 were met in the Phase III study Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below